GLUCAGON KIT

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

GLUCAGON (RECOMBINANT DNA ORIGIN)

Prieinama:

ELI LILLY CANADA INC

ATC kodas:

H04AA01

INN (Tarptautinis Pavadinimas):

GLUCAGON

Dozė:

1MG

Vaisto forma:

KIT

Sudėtis:

GLUCAGON (RECOMBINANT DNA ORIGIN) 1MG

Vartojimo būdas:

INTRAMUSCULAR

Vienetai pakuotėje:

1 ML

Recepto tipas:

Schedule D

Gydymo sritis:

GLYCOGENOLYTIC AGENTS

Produkto santrauka:

Active ingredient group (AIG) number: 0142861001; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2023-12-18

Prekės savybės

GLUCACON (rDNA Origin) Product Monograph
Page 1 of 32
PRODUCT MONOGRAPH
GLUCAGON
GLUCAGON FOR INJECTION, RDNA ORIGIN
1 MG GLUCAGON PER VIAL
Sterile Lyophilized Powder and Diluent
Hyperglycemic Agent
©
Eli Lilly Canada Inc.
3650 Danforth Avenue
Toronto, Ontario
M1N 2E8
1-888-545-5972
Date of Approval:
July 9, 2012
www.lilly.ca
Submission Control No: 139332
GLUCACON (rDNA Origin) Product Monograph
Page 2 of 32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
DRUG INTERACTION
............................................................................................................
8
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 12
STORAGE AND STABILITY
...............................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
14
PHARMACEUTICAL INFORMATION
...............................................................................
14
CLINICAL TRIALS
...........................................................................................................